Products for Research Use Only

Baminercept

CAT: 0804-HY-P99459-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99459-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig) . Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) [1][2].
CAS Number
909110-25-4
Product Name Alternative
BG 9924; TT-47
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/baminercept.html
Purity
99.97
Solubility
10 mM in DMSO
Smiles
[Baminercept]
Molecular Weight
(93.76 kDa)
References & Citations
[1]E William St Clair, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 Sep;70 (9) :1470-1480.|[2]Jadwiga Bienkowska, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014 Nov 18;9 (11) :e112545.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2